BenResearch_OR said:Orforglipron is the more interesting oral story because it is not a peptide at all.
I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.
One concrete data point for the thread. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.
BariatricNurseD said:I do not accept that the fasting window is a minor inconvenience.
There is a second half to this that has not been said yet. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsA narrower follow-up, since the general answer is now clear:
How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?
OP back with an update, since a thread like this is useless without one.
Update — I went back to the injectable. Not because the tablet did not work, but because the fasting window and my mornings were never going to agree.